ID Week

At IDWeek 2026, Samuel Ntow, MBChB, MPH, discussed research findings of reactive infection screening markers in 18.3% of replacement donor records from rural Ghana, highlighting opportunities for further evaluation and linkage to care.

John Rex, MD, CMO of F2G, discusses investigational olorofim’s phase 3 findings, why new antifungals are difficult to develop, and how an oral option could help patients with limited treatment choices.

An analysis of 147 million US hospital admissions identified 875 adults with brucellosis diagnoses, highlighting demographic and regional differences while emphasizing exposure histories and uncertainty about underdiagnosis.

An ICU study found that alcohol-based hand rub applied after patient care reduced glove bioburden, while staff raised feasibility concerns. Researchers stress that the practice does not replace glove changes or hand hygiene.

A study of 4,851 nursing home residents linked shared rooms to higher odds of matching MDRO carriage, while universal decolonization was associated with lower concordant carriage across MRSA, ESBL, and VRE.

A retrospective hospital study found no significant differences in mortality or readmissions between infectious disease e-consults and in-person consultations, despite more diagnoses of bacteremia among e-consult patients. Researchers recommend further evaluation across settings.

Presented at IDWeek 2026, a living review of 64 studies found the strongest evidence for dengue prevention from mosquito modification, while highlighting substantial uncertainty and research gaps in other approaches to Aedes vector control.

A 2026 IDWeek poster details how respiratory cultures and whole genome sequencing clarified a NICU MRSA outbreak, with targeted prevention measures followed by at least 6 months without additional bacteremias or related respiratory clusters.

Researchers recovered a carbapenemase-producing organism from the shaft of a hospital drain auger, prompting calls for standardized reprocessing protocols and further investigation into maintenance equipment as a potential source of environmental dissemination.

A poster presented at IDWeek was a systematic review of 35 studies that found rare transmission of viral hemorrhagic fever to health care personnel in high-income countries and highlighted the need for standardized exposure definitions to guide response.

Kimberley Brown, PharmD, Head of U.S. Medical Affairs at ViiV Healthcare discusses the evolution of HIV care and how innovative long-acting injectables are expanding options across HIV treatment and prevention.

When operating room delays and tray errors threatened efficiency, leaders at New York Presbyterian built a collaborative bridge with central sterile processing. Through shared metrics, workflow exchanges, and improved communication, first-case-on-time starts climbed from the 50 to nearly 90%.

When a nationwide blood-culture bottle shortage squeezed hospitals, a Stanford-led team turned to machine learning by building and openly sharing tools that predict which patients are most likely to have bacteremia and when a culture can be safely deferred. The simplest version works as a quick bedside score, no new software required.

A Bangladesh research team unveiled a suitcase-sized, point-of-care test that detects Nipah virus from respiratory patients in about 30 minutes, showing accuracy comparable to RT-PCR, and designed to bring rapid diagnosis and outbreak control to rural, low-resource settings.

From hand-hygiene audits to the SHEA Board of Trustees, the professional path of Alexander Sundermann, DrPH, CIC, FAPIC, AL-CIP, traces the arc of modern infection prevention. The former hospital IP—now a University of Pittsburgh assistant professor—pairs frontline experience with genomic epidemiology to turn sequencing into outbreak-stopping action.

When Hurricane Helene flooded a North Carolina facility and sparked an IV fluid shortage, Duke’s stewardship network turned crisis into practice change—rapidly shifting eligible patients to highly bioavailable oral antibiotics and boosting PO use by 5.6% across participating hospitals.

At IDWeek in Atlanta, former CDC director Tom Frieden unveiled a crisp playbook for infection prevention—“See. Believe. Create.”—arguing it can help hospitals spot outbreaks sooner, reverse drug resistance, and drive HAIs toward zero. He paired the message with a 7-1-7 target: 7 days to find an outbreak, 1 to report, 7 to control.

IDWeek 2024 continues to give encouraging studies. Check out several more from CSL Seqirus and Shionogi.

Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.

Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.

Peter Rabinowitz, MD, MPH, discusses how climate change, including extreme weather and temperature shifts, is reshaping the spread of infectious diseases like dengue, leptospirosis, and Valley fever.

The rise of multidrug-resistant gonorrhea highlights the urgent need for new therapies. Zoliflodacin, a promising oral antibiotic, shows effectiveness in late-stage trials.

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending October 29, 2023.

Staying Ahead With Company Updates and Product Innovations. This week's news is from Moderna, CBIC, Helocyte, Pfizer, UVDI, and CloroxPro.

Benjamin Chen, MD, MPH, speaks about how a journal watch in infection prevention keeps professionals updated on research, fosters evidence-based practices, and supports education and quality improvement efforts.

Recent INFORM and EPOCH studies shed light on the significant risk and poor outcomes faced by immunocompromised individuals due to COVID-19, emphasizing the need for tailored prevention strategies.

At IDWeek 2023, a presenter uses HIV as a model to understand the post-acute sequelae of viral infections.

At IDWeek 2023, a session illuminates the importance of accurate diagnosis, current treatments, and what is on the horizon for HSV.

Belinda Ostrowsky, MD, MPH, FIDSA, FSHEA, and SHEA Chair, highlights IDWeek 2023's hybrid format and discusses the critical topic of antimicrobial resistance, emphasizing the role of vaccines in reducing AMR.